This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.
The purpose of this study is to obtain archived tumor tissue or pre-existing antigen expression data from patients with Head and Neck, Cervical, Melanoma and Non-Small Cell Lung Cancers to assess antigen expression and patient suitability for a Repertoire Immune Medicines Treatment Protocol.
Checked against the public recordLast updated Dec 6, 2022 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- Repertoire Immune Medicines
- Interventions being studied
- Diagnostic Test: Tumor Profiling
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Be willing and able to provide written informed consent * Age ≥ 18 years * Histologically- or cytologically-confirmed, relapsed/refractory, and metastatic or locally advanced head and neck, cervical, melanoma or non-small cell lung cancers. Other solid tumor types may be analyzed at the discretion of the Sponsor * Able to provide archived tumor tissue or have existing data on TAAs, HPV status or HLA sub-type * Willing to provide a saliva sample Exclusion Criteria: * There are no exclusion criteria for this study.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- HonorHealth Research InstituteScottsdale, Arizona
- University of Michigan Comprehensive Cancer CenterAnn Arbor, Michigan
- Sarah Cannon Cancer CenterNashville, Tennessee
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Dec 6, 2022. Always confirm current availability with the study team.